Real-World lupus drug study launches in poland

NCT ID NCT06673043

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 100 Polish adults with systemic lupus erythematosus (SLE) who are receiving anifrolumab as part of their routine care. Researchers will track changes in disease activity and overall response over time. The goal is to see how well the drug works outside of controlled clinical trials.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUPUS ERYTHEMATOSUS, SYSTEMIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

systemic lupus erythematosus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUPUS ERYTHEMATOSUS, SYSTEMIC

Contacts and locations

Show contact details

Locations

Research Site

Bydgoszcz, Poland
Research Site

Bytom, Poland
Research Site

Gdansk, Poland
Research Site

Katowice, Poland
Research Site

Krakow, Poland
Research Site

Lodz, Poland
Research Site

Lublin, Poland
Research Site

Poznan, Poland
Research Site

Rzeszów, Poland
Research Site

Warsaw, Poland
Research Site

Wroclaw, Poland